Health care sector: how it makes money and what to watch

The health care sector includes companies that develop drugs, make medical equipment, deliver care and insure patients. It is usually grouped with the defensive sectors, because people need medical care in good times and bad. But the sector is really several industries with very different economics, from profitable insurers to biotech firms that have no revenue at all. Knowing which type of company you are examining is the first step in analyzing it.

What is inside the sector

StocksXray has a sector page for health care if you want to explore the companies in this group.

How the main models work

Drugmakers and patents. A new drug is protected by patents and regulatory exclusivity for a period, during which the company can charge prices well above manufacturing cost. When protection ends, generic or biosimilar competitors usually enter and revenue from that product often falls steeply. This is often called a patent cliff. Companies therefore depend on a pipeline of new products. Drug development passes through clinical trial phases and regulatory review by the Food and Drug Administration (FDA), and most candidates never reach the market. This makes results for small biotechnology firms binary: a trial result can move a stock dramatically.

Medical devices. Device makers earn from equipment sales and, often more reliably, from recurring supplies and service tied to the installed base. Hospital budgets and procedure volumes drive demand.

Insurers and managed care. These companies collect premiums and pay medical claims. Their key figure is the medical loss ratio, the share of premiums spent on medical costs. If costs rise faster than premiums, margins shrink.

Government as a payer. Programs such as Medicare and Medicaid, and the negotiation of prices and reimbursement, shape revenue across the whole sector. Policy changes can affect entire segments at once.

Metrics worth watching

• Revenue concentration. Does a single product account for a large share of sales, and when does its patent protection expire?
• R&D spending. Compare research spending with revenue, and ask whether the pipeline is broad or depends on a few late-stage candidates.
• Gross margin. Typically high for drugs and lower for services and distributors.
• Cash runway for unprofitable firms. For biotechs without product revenue, the question is how many quarters of cash remain relative to the burn rate. A company that must raise money often does so by issuing shares, diluting existing owners.
• Free cash flow. Profits that convert to free cash flow show whether earnings are real.
• Acquired intangibles. Pharma companies often grow through acquisitions, leaving large goodwill and intangible assets on the balance sheet that can be written down if deals disappoint.
• Medical loss ratio. For insurers, trends in this ratio matter more than a single quarter.

Example (illustrative numbers). An insurer collects $100 in premiums and pays $85 in claims, for a medical loss ratio of 85%. That leaves $15 to cover administrative costs and profit. If claims rise to $90 per $100 of premiums, the ratio becomes 90% and the room for costs and profit is cut by a third, from $15 to $10.

Valuation notes

Profitable large companies are often valued on price-to-earnings or free cash flow multiples. For pre-profit biotechs, earnings multiples do not work, and analysts tend to estimate the risk-adjusted value of the pipeline, which is highly uncertain. Price-to-sales can be a rough reference, but it ignores whether any drug will ever earn a profit. Compare companies with the right sub-group, as explained in relative valuation and peer multiples.

Risks and limits

• Binary events. Trial failures and regulatory decisions can erase value quickly.
• Patent expiration. Revenue cliffs are predictable in timing and still painful.
• Pricing and reimbursement policy. Governments and insurers push on prices.
• Litigation and safety issues. Product liability and recalls can be costly.
• The defensive label is imperfect. Health care often holds up better in downturns, but large drawdowns still occur, particularly in biotechnology.
• Accounting complexity. Research costs are expensed while the benefit comes later, and adjusted profit figures vary between companies.

Where to see it on StocksXray

Every metric on the site is ranked as a percentile within the company's own sector, so a medical device maker is compared with other health care companies. Stock pages include a fundamentals checklist and red flags such as dilution and negative equity, both relevant for cash-burning biotechs. The X-Ray Score methodology shows how the five lenses are weighted.

Key takeaways

• Health care contains pharma, biotech, devices, insurers, providers and tools, each with its own economics.
• Patents and pipelines drive drugmakers, procedure volumes drive device makers, and cost trends drive insurers.
• Watch revenue concentration, patent expiry dates, cash runway and free cash flow.
• Government policy affects the whole sector at once.
• Defensive does not mean low-risk, especially in small biotechnology.